| Latest Maelor Plc News Headlines |
| Date | Time | Source | |
| 04/22/2008 | 3:00AM | UKREG | Director/PDMR Shareholding
Maelor PLC
22 April 2008
22 April 2008
Maelor plc ("Maelor" or the "Company")
Director dealings
On 22 April 2008 the Company received notification of the following share
purchases of its 70 pence Ordinary Shares by Directors as part of today's
placing:
Name... More...>> |
| 04/22/2008 | 2:02AM | UKREG | Consolidation and Placing
Maelor PLC
22 April 2008
22 April 2008
Maelor plc ( 'Maelor' or the 'Company')
Consolidation and Placing
The Board of Maelor plc (AIM:MLR), the specialist hospital medicines group, is
pleased to announce that it has conditionally raised £10.0 million... More...>> |
| 04/21/2008 | 7:36AM | UKREG | Result of General Meeting
Maelor PLC
21 April 2008
21 April 2008
Maelor plc ('Maelor' or the 'Company')
Result of General Meeting
The Board of Maelor plc (AIM:MLR), the specialist hospital medicines group, is
pleased to announce that the ordinary resolutions and special resolutions
considered... More...>> |
| 03/28/2008 | 5:28AM | TFNF | Maelor sees FY ahead of view; buys SEPI AG for up to 14.25 mln stg UPDATE
(Adds details on share consolidation, placing, name change)
Specialist hospital medicines group Maelor PLC
said it expects its full-year results to be ahead of expectations on continuing
strong trading as it announced the acquisition of Speciality European Pharma
International AG (SEPI AG) for up to 14.25... More...>> |
| 03/28/2008 | 3:59AM | TFNF | Maelor sees FY results ahead of view; buys SEPI AG for up to 14.25 mln stg
Specialist hospital medicines group Maelor PLC
said it expects its full-year results to be ahead of expectations and announced
the acquisition of Speciality European Pharma International AG (SEPI AG) for up
to 14.25 mln stg cash.
SEPI AG, a unit of Speciality European Pharma Ltd (SEP), is a specialist
hospital... More...>> |
| 03/28/2008 | 3:04AM | UKREG | Acquisition
Maelor PLC
28 March 2008
28 March 2008
Maelor plc ('Maelor' or the 'Company')
Acquisition of Speciality European Pharma International AG
The Board of Maelor plc (AIM:MLR), the specialist hospital medicines group, is
pleased to announce the acquisition of Speciality... More...>> |
| 02/11/2008 | 3:21AM | TFNF | Maelor launches anti-emetic drug Aloxi in UK ahead of schedule
Specialist hospital medicines company Maelor
PLC said it has launched Aloxi, a new generation anti-emetic drug for treatment
of chemotherapy induced nausea and vomiting, in the UK ahead of schedule.
The company said Aloxi is licensed from Swiss pharmaceutical group Helsinn
Healthcare SA and generated worldwide... More...>> |
| 02/11/2008 | 2:02AM | UKREG | Aloxi - Product launch
Maelor PLC
11 February 2008
11th February 2008
Maelor plc ("Maelor" or the "Company")
Maelor Launches Aloxi(R) (palonosetron) in the UK
MAELOR PLC (AIM:MLR), the specialist hospital medicines group is pleased to
announce, ahead of schedule, the UK launch of Aloxi(R... More...>> |
| 12/11/2007 | 12:58PM | UKREG | Holding(s) in Company
Maelor PLC
11 December 2007
Maelor plc
11 December 2007
Maelor plc
(the 'Company' or 'Maelor')
Notification of Interest
The Company was notified on 10 December 2007 that Liontrust Investment... More...>> |
| 11/06/2007 | 7:51AM | TFNF | Maelor CEO Tim Wright lifts stake
Maelor PLC said chief executive Tim Wright
bought 145,000 shares at 13.75 pence each, raising his stake in the company to
0.9 pct or 1.145 mln shares.
Earlier today, the specialist hospital medicines company reported a
first-half pretax profit of 700,000 stg, compared with a 70,000 loss last year,
boosted... More...>> |
| 11/06/2007 | 7:03AM | UKREG | Director/PDMR Shareholding
Maelor PLC
06 November 2007
06 November 2007
Maelor plc ("Maelor" or the "Company")
Director dealings
The Company was informed on 6 November 2007, that Tim Wright, Chief Executive of
Maelor, purchased 145,000 Ordinary Shares of 10p each... More...>> |
| 11/06/2007 | 3:45AM | TFNF | Maelor swings to 700,000 stg H1 pretax profit; plans more acquisitions UPDATE
(adds CEO comment)
Maelor PLC reported a first-half pretax profit
of 700,000 stg, compared with a 70,000 loss last year, due to acquisitions and
restructuring effects.
The specialist hospital medicines company said first-half sales were 3 mln
stg, surpassing the total for the whole of last year, while... More...>> |
| 11/06/2007 | 2:47AM | TFNF | Maelor swings to 700,000 stg H1 pretax profit, plans more acquisitions
Maelor PLC, the specialist hospital medicines
company, made a first half pretax profit of 700,000 stg, compared with a 70,000
loss last year, due to acquisitions and restructuring effects.
First half sales were 3 mln stg, which surpassed the total for the whole of
last year, while interim EPS was 48 pence... More...>> |
| 11/06/2007 | 2:02AM | UKREG | Interim Results
Maelor PLC
06 November 2007
6th November 2007
Maelor plc (the 'Company' or the 'Group') - Interim Results
Maelor transformed to deliver profits ahead of expectations
Maelor plc, the UK based specialist hospital medicines group, is pleased to
announce its interim results for the... More...>> |
| 10/31/2007 | 7:13AM | TFNF | Maelor completes 5-yr distribution agreement with Bard for OptiFlo products
Maelor PLC said it has completed a new
five-year agreement with Bard Ltd for the distribution of the OptiFlo catheter
maintenance products.
Maelor has distribution agreements for the UK and Ireland with Bard for the
ContiSol range of products sold under the name OptiFlo.
The specialist hospital medicines... More...>> |
| 10/31/2007 | 3:04AM | RNSNON | New distribution agreement
Maelor PLC
31 October 2007
Maelor plc
31 October 2007
Maelor plc (the "Company")
New distribution agreement for OptiFlo(TM) Catheter Maintenance Solutions
The Board of Maelor plc ("Maelor"; AIM:MLR), the specialist hospital medicines
group, is pleased to announce the completion... More...>> |
| 10/29/2007 | 8:36AM | TFNF | Maelor, Helsinn sign licence, distribution deal for Aloxi in the UK UPDATE
(Adds background, Helsinn Healthcare comment)
Maelor PLC, the specialist hospital medicines
company, said it has agreed a licensing deal to market and distribute Swiss
pharma company Helsinn's anti-nausea and vomiting treatment Aloxi.
Aloxi is used for cancer patients undergoing chemotherapy, 85 pct... More...>> |
| 10/29/2007 | 8:32AM | TFNF | CORRECTION Maelor, Helsinn sign licence, distribution deal for Aloxi in the UK
(corrects to show Maelor CEO is Tim Wright not Dr Riccardo Braglia. Braglia
is the CEO of Helsinn Healthcare)
Maelor PLC, the specialist hospital medicines
company, has agreed a licensing deal to market and distribute Swiss pharma
company Helsinn's anti-nausea and vomiting treatment Aloxi.
Aloxi is... More...>> |
| 10/29/2007 | 5:20AM | TFNF | Maelor, Helsinn sign licence, distribution deal for Aloxi in the UK
Maelor PLC, the specialist hospital medicines
company, has agreed a licensing deal to market and distribute Swiss pharma
company Helsinn's anti-nausea and vomiting treatment Aloxi.
Aloxi is used for cancer patients undergoing chemotherapy, 85 pct of whom
experience nausea or vomiting after treatment. Global... More...>> |
| 10/29/2007 | 4:45AM | UKREG | New license agreement
Maelor PLC
29 October 2007
Maelor plc
29 October 2007
Maelor plc
MAELOR and HELSINN ANNOUNCE A LICENSE AGREEMENT FOR ALOXI(R) (PALONOSETRON) IN
THE UK
LONDON, UNITED KINGDOM AND LUGANO, SWITZERLAND, OCTOBER 29th, 2007 - MAELOR PLC
(AIM:MLR), a UK... More...>> |